- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2014
- Public Summary Document (PSD) November 2014 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2014 PBAC Meeting - Word
Omalizumab – November 2014
Omalizumab; 75 mg/0.5 mL injection, 1 x 0.5 mL syringe, 150 mg/mL injection, 1 x 1 mL syringe, 150 mg injection [1 x 150 mg vial] (&) inert substance diluent [1 x 1.2 mL ampoule], 1 pack; Xolair®
Last updated
6 March 2015
